InChI=1S/C45H69N11O12S/c1-6-25(4)38-44(66)51-28(15-16-34(46)57)40(62)52-31(21-35(47)58)41(63)54-32(23-69-18-8-10-37(60)50-30(42(64)55-38)20-26-11-13-27(68-5)14-12-26)45(67)56-17-7-9-33(56)43(65)53-29(19-24(2)3)39(61)49-22-36(48)59/h11-14,24-25,28-33,38H,6-10,15-23H2,1-5H3,(H2,46,57)(H2,47,58)(H2,48,59)(H,49,61)(H,50,60)(H,51,66)(H,52,62)(H,53,65)(H,54,63)(H,55,64)/t25-,28-,29-,30-,31-,32-,33-,38-/m0/s1 |
NSTRIRCPWQHTIA-DTRKZRJBSA-N |
[H][C@]1(NC(=O)[C@H](Cc2ccc(OC)cc2)NC(=O)CCCSC[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC1=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)[C@@H](C)CC |
|
Bronsted base
A molecular entity capable of accepting a hydron from a donor (Bronsted acid).
(via organic amino compound )
|
|
oxytocic
A drug that stimulates contraction of the myometrium. Oxytocics are used to induce labour, obstetric at term, to prevent or control postpartum or postabortion haemorrhage, and to assess foetal status in high risk pregnancies. They may also be used alone or with other drugs to induce abortions (abortifacients).
|
|
View more via ChEBI Ontology
1-{[(3R,6S,9S,12S,15S)-6-(2-amino-2-oxoethyl)-9-(3-amino-3-oxopropyl)-12-[(2S)-butan-2-yl]-15-(4-methoxybenzyl)-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentaazacycloicosan-3-yl]carbonyl}-L-prolyl-L-leucylglycinamide
|
carbetocin
|
ChemIDplus
|
carbetocino
|
ChemIDplus
|
carbetocinum
|
ChemIDplus
|
1-butanoic acid-2-(O-methyl-L-tyrosine)-1-carbaoxytocin
|
ChEBI
|
1-butyric acid-2-(3-(p-methoxyphenyl)-L-alanine)oxytocin
|
ChemIDplus
|
deamino-2-O-methyltyrosine-1-carbaoxytocin
|
ChEBI
|
1778
|
VSDB
|
495
|
DrugCentral
|
C18365
|
KEGG COMPOUND
|
D07229
|
KEGG DRUG
|
DB01282
|
DrugBank
|
DE2732175
|
Patent
|
View more database links |
37025-55-1
|
CAS Registry Number
|
KEGG DRUG
|
37025-55-1
|
CAS Registry Number
|
ChemIDplus
|
9985308
|
Beilstein Registry Number
|
Beilstein
|
|